Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A Novel Therapeutic that Harnesses Microtubules to Promote Cavernous Nerve Regeneration after Radical Prostatectomy

Award Number: R41DK117684
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/20/2018
PERIOD OF PERFORMANCE END DATE: 08/31/2019

Group Awards By:

View Award Description

A Novel Therapeutic that Harnesses Microtubules to Promote Cavernous Nerve Regeneration after Radical Prostatectomy - Radical prostatectomy (RP) is a commonly used treatment option for localized prostate cancer. Unfortunately, the procedure carries a risk of post-surgical complications including a high risk of erectile dysfunction (ED). According to The Prostate Cancer Outcomes Study, virtually all men experience ED after surgery, including a profound loss of nocturnal erections. The Prostate Cancer Outcomes Study further reveals that 60% of men experienced self-reported ED 18 months after RP, and only 28% of men reported erections firm enough for intercourse at a 5-year follow-up. The main pathophysiological mechanism behind this is damage to the cavernous nerves (CN). Consequently, the mechanisms that facilitate cavernosal oxygenation fail; fibrosis ensues and leads to cavernosal smooth muscle apoptosis. Whereas neuropraxia may be reversible, the penile fibrosis resulting from poor oxygenation permanently damages cavernosal function and produces chronic ED. Accelerated wound healing and nerve growth would preserve penile anatomy and corporal smooth muscle and potentially reduce the time patients experience ED following RP. However, there are at present no clinically approved strategies for this procedure. Several promising studies in animal models have used gene therapy approaches, usually involving overexpression of “nerve growth factors.” Clinical translation of these gene therapy approaches will be hampered by safety issues over the use of viral vectors or transformed stem cells in a “benign urological disease” as well as concerns over the ease of application. In addition, there are no orally or topically administered therapeutics that reliably elicit an erection in men with RP-induced ED. Our goal is to develop a novel therapeutic that enhances EF after RP via RNAi-mediated silencing of the microtubule severing enzyme, Fidgetin-like 2 (FL2). Preliminary results in an animal model of RP demonstrate that FL2 can be targeted by nanoparticle-delivered siRNA to dramatically and predictably recover EF. FL2 acts through mechanisms dramatically different from other genes/proteins/factors currently being investigated; the experiments presented in this application represent the first reported success of siRNA in treating ED associated with RP. In addition, our recent preliminary findings indicate that a polyplex-based carrier (“wafer”) of FL2-siRNA is at least as effective as FL2-siRNA-np in restoring EF in an animal RP model. In Specific Aim 1 we will compare a range of concentrations of FL2-siRNA incorporated in a wafer formulation for efficacy in restoring EF following CN injury (transection). Finally, in Specific Aim 2, we will perform toxicity studies to provide evidence of safety for the different siRNA concentrations. Thus, at the end of the project, we will have identified the siRNA-wafer formulation that restores EF and is safe for further IND-enabling studies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2018	MICROCURES INC.	105 SYLVAR ST	SANTA CRUZ	CA	95060	SANTA CRUZ	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	12/17/2019	NEW	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $234,898 )
2018	2018	MICROCURES INC.	105 SYLVAR ST	SANTA CRUZ	CA	95060	SANTA CRUZ	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	9/19/2018	NEW	$234,898
														Subtotal = $234,898

Grand Total All Awards = $234,898

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Novel Therapeutic that Harnesses Microtubules to Promote Cavernous Nerve Regeneration after Radical Prostatectomy

Award Number: R41DK117684

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/20/2018

PERIOD OF PERFORMANCE END DATE: 08/31/2019

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer